Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Konstan

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Current Opinion in Pulmonary Medicine|September 25, 2008
Ibuprofen therapy for cystic fibrosis lung disease: revisitedMichael W Konstan
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2011
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosisMichael W Konstan, Felix Ratjen
Clinical Investigation|July 7, 2015
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung diseaseDonald R VanDevanter, Michael W Konstan
The Lancet. Respiratory Medicine|October 2, 2019
Clinical care for cystic fibrosis: preparing for the future nowMichael W Konstan, Patrick A Flume
American Journal of Respiratory and Critical Care Medicine|February 2, 2017
Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?Gregory S Sawicki, Michael W Konstan,
Advanced Drug Delivery Reviews|November 30, 2002
Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosisMichael W Konstan, Pamela B Davis
JAMA|May 22, 2012
Inhaled hypertonic saline in infants and young children with cystic fibrosisElliott C Dasenbrook, Michael W Konstan
Clinics in Chest Medicine|May 1, 2007
Inflammation and anti-inflammatory therapies for cystic fibrosisJames F Chmiel, Michael W Konstan
Treatments in Respiratory Medicine|August 10, 2005
Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agentJames F Chmiel, Michael W Konstan
JAMA|January 11, 2022
What Is Cystic Fibrosis?Tori M Endres, Michael W Konstan
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Current Opinion in Pulmonary Medicine|September 25, 2008
Ibuprofen therapy for cystic fibrosis lung disease: revisitedMichael W Konstan
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2011
Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosisMichael W Konstan, Felix Ratjen
Clinical Investigation|July 7, 2015
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung diseaseDonald R VanDevanter, Michael W Konstan
The Lancet. Respiratory Medicine|October 2, 2019
Clinical care for cystic fibrosis: preparing for the future nowMichael W Konstan, Patrick A Flume
American Journal of Respiratory and Critical Care Medicine|February 2, 2017
Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?Gregory S Sawicki, Michael W Konstan,
Advanced Drug Delivery Reviews|November 30, 2002
Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosisMichael W Konstan, Pamela B Davis
JAMA|May 22, 2012
Inhaled hypertonic saline in infants and young children with cystic fibrosisElliott C Dasenbrook, Michael W Konstan
Clinics in Chest Medicine|May 1, 2007
Inflammation and anti-inflammatory therapies for cystic fibrosisJames F Chmiel, Michael W Konstan
Treatments in Respiratory Medicine|August 10, 2005
Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agentJames F Chmiel, Michael W Konstan
JAMA|January 11, 2022
What Is Cystic Fibrosis?Tori M Endres, Michael W Konstan
Pageof 18